Skip to main content

Advertisement

Table 5 Comparison of different adjuvant chemoradiation studies

From: Postoperative chemoradiation for resected gastric cancer - is the Macdonald Regimen Tolerable? a retrospective multi-institutional study

First author
(country, year)
Type of study No. of patients Type of chemotherapy T3-4 N+ Any Gr ≥ 3 tox. Gr > 3 Hem. tox. Gr > 3 Non- hem. tox. Toxic deaths Relapse rate Median survival (months)
MacDonald [4]
(USA, 2001)
Phase 3 556 5FU/LV1 66% 85% 41% 54% 63% 1% 43% 36
Park [18]
(South-Korea,2003)
Phase 2 290 5FU/LV NA 90% NA 30% 38% 0% 39% NA
Hughes [14]
(Australia, 2004)
Retrosp. 452 5FU/LV 85% 81% 42% 18% 20% 0% 68% 22.8
Kollmannsberger [20]
(Germany, 2005)
Phase 2 86 DDP/5FU
PAC/DDP/5FU/LV4
NA NA NA 81% 89% 56% 56% 0%
0%
19%
33%
NA
NA
Kim [9]
(South Korea, 2005)
Retrosp. 990 5FU/LV 48% 93% NA 30% 15% 1% 42% 95
Kassam [15]
(Canada, 2006)
Retrosp. 822 5FU/LV3
DDP/5FU
53% 82% 56% 33% 34% 0% 32% NR
Lee [19]
(South-Korea, 2006)
Phase 2 31 DDP/5FU NA 100% NA 66% 12% 0% 13% NA
Oechsle [8]
(Germany,2007)
Phase 2 157 DDP/PAC/5FU/LV NA NA NA 100% 58% 0.6%5 51% NA
    DDP/5FU/LV     93% 59%   52% NA
    CPT11/5FU/LV     80% 73%   100% NA
    DOC/DDP/5FU     100% 30%   30% NA
Tsang13]
(Hong Kong, 2008)
Retrosp. 632 5FU/LV 52% 86% 30% 24% 14% 1.5% 52% NR
Hofheinz [16]
Germany, 2008)
Extend. phase I 322 CAPE/OXALI 44% 97% NA 21% 42% 0% 47% NA
Di Costanzo [7]
(Italy, 2008)
Phase 3 258 DDP/EPI/5FU/LV1 54% 84% NR 27% 75% 0.8% 48% 57
Leong [22]
(Australia, 2009)
Phase 2 54 EPI/DDP/5FU 57% 98% NA 28% 66% 0% 37% NR
Aftimos [21]
(Lebanon, 2010)
Retrosp. 24 5FU/LV
DDP/5FU
75% 71% NA 20% 36% 0% 22% 75
Chang [17]
(Hong Kong, 2011)
Retrosp. 1202 5FU/LV 45% 93% 66% 61% 15% 0% 41% 64
Current
(Israel, 2011)
Retrosp. 166 5FU/LV 77% 85% 46% 32% 25% 1.8% 30% NR
  1. Tox. = toxicity, Hem. = hematological, Extend. = extended, Retrosp. = retrospective, DDP = cisplatin, PAC = paclitaxel, EPI = epirubicin, CAP = capecitabine, OX = oxaliplatin, DOC = docetaxel, 5FU = 5 fluorouracil, LV = Leucovorin. NR = not reached, NA = not available.
  2. 1The regimen used in the treatment arm. The control arm included surgery alone.
  3. 2These studies included also patients undergoing R1 resection; results of outcome represent patients undergoing R0 resection,
  4. whenever reported separately.
  5. 3Combined analysis of more than one regimen.
  6. 4Combined report of consecutive phase II cohorts.
  7. 5Joint figure for all cohorts combined